The Genetics of Cognitive Neuroscience

edited by Terry E. Goldberg and Daniel R. Weinberger

The MIT Press
Cambridge, Massachusetts
London, England

This book was set in Stone Sans and Stone Serif by SNP Best-set Typesetter Ltd., Hong Kong and was printed and bound in the United States of America.

Library of Congress Cataloging-in-Publication Data
The genetics of cognitive neuroscience / edited by Terry E. Goldberg and Daniel R. Weinberger.
p. cm. – (Issues in clinical and cognitive neuropsychology)
Includes bibliographical references and index.
ISBN 978-0-262-01307-9 (hardcover : alk. paper) 1. Neurogenetics. 2. Cognitive neuroscience. I. Goldberg, Terry E. II. Weinberger, Daniel R.
QP356.22.G463 2009
612.8–dc22

2008044259

10 9 8 7 6 5 4 3 2 1

Index

Aberdeen birth cohorts (ABC), 110
Abnormal spindle-like microcephaly (ASPM), 110
Active avoidance, 60
Active rGE, 106
Addiction, 70, 123, 147
Addington, AM, 109
Adenines, 14
Adoption studies, xi
  environmental factors and, 98–99
  intelligence and, 98–100
  socioeconomic status and, 98
Affected sib pairs (ASP) method, 36, 46
Affective disorders, 146
  schizoaffective, 250–251
  serotonin and, 148–153
Afifi, AK, 223
Aggleton, JP, 80
Agnosia, 228
Akassoglou, K, 54
Albinos, 43
Alcoholism, 108–109, 112
ALDH5A1, 108
Aleman, A, 202
Alleles, 80
  Alzheimer's disease and, 221–235
  animal models and, 51
  anxiety and, 150–153
  APOE and, 167–168
  association of, 33
  attention and, 129–130
  candidate gene approach and, 109–112
  dyslexia and, 184–186
  environmental factors and, 43–46
  Fisher's exact test and, 29
  frequency of, 32–34
  genetic component determination and, 30–32
  genome-wide association (GWA) and, 27, 29, 39–43
  haplotype analysis and, 33, 38
  Hardy-Weinberg equilibrium (HWE) and, 32–33, 36
  Hasemen-Elston regression and, 37
  heterozygotes and, 32
  homozygotes and, 32
  identical by descent (IBD), 30, 36–37
  interclass correlation coefficient (ICC) and, 30–31
  linkage disequilibrium (LD) and, 33–34
  markers and, 27–29, 32–43
  pedigree structure and, 34–35
  phase and, 38
  pooled association and, 107–109
  power calculation and, 46–47
  sample size and, 46–47
  schizophrenia and, 195–208, 245–255
  statistical genetics and, 27–47
  subpopulation data and, 41–43
  3–repeat, 129, 129–130
  Valine, 129
Allele-sharing values, 29
Allen Brain Atlas software, 22

Almasy, L, 37
Alpha-antichymotrypsin, 223
Alzheimer's disease, 28, 74, 161–162, 168, 207
 age groups and, 228–229
 amyloid precursor protein and, 225–229
 animal models and, 222, 234–235
 antisocial behavior and, 226
 anxiety and, 226
 apathy and, 226
 apolipoprotein E (APOE) and, 231–234
 BDNF and, 223
 behavioral abnormalities and, 226
 beta-amyloid protein and, 223–224, 227–228, 232
 clinical practice implications and, 234
 dementia concept and, 8, 223–224
 depression and, 226
 Down's syndrome and, 223, 225, 227–228
 etiology of, 224
 familial, 224–226, 229–231, 234
 genetic basis for cognitive decline, 221–235
 Huntington's disease and, 223
 information processing and, 223–225
 insulin degrading enzyme (IDE) and, 233
 language deficits and, 223
 linkage analysis and, 225–226
 Mini–Mental State Examination (MMSE) and, 230
 motor deficits and, 223
 neurofibrillary triangles (NFTs) and, 223–225, 227
 paired helical filaments (PHFs) and, 223–224
 pathology of, 223–225
 presenilins and, 228–231
 protein products and, 221–223
 race and, 230–231
 Rett syndrome (RS) and, 222–223
 senile plaques and, 223–224, 227
 SORL1 and, 233–234
 sporadic, 224–226, 233
 Trails Making Test and, 230
 ubiquilin and, 233
 visuospatial deficits and, 223
 Wisconsin Card Sorting test and, 230
 young-onset, 229
Ambrosius, WT, 46
Amino acids
 functional variations and, 12–16
 transcription phase and, 13–14
Amir, RE, 223
Amygdala
 animal models and, 68–70, 74
 temperamental anxiety and, 150–152
Amyloid precursor protein (APP), 52, 224–229
Anagnostaras, SG, 59
Andersen, RA, 125
Andreasen, NC, 102
Andrews, W, 182
Angelman syndrome, 12
Animal models
 advantages over pharmacological models, 51
 allele dose and, 51
 Alzheimer's disease and, 222, 234–235
 amygdala and, 68–70, 74
 attention and, 65–67, 135–136
 Barnes maze and, 60
 behavioral tests and, 58–68, 80
 brain-derived neurotrophic factor (BDNF) mice and, 75–76
 calcium/calmodulin-dependent protein kinase II and, 68–69
 candidate gene approach and, 109
 chimpanzees and, 10
 cognition and, 51–81, 160–161
 color and, 65
 conditioned punishment and, 67
 confounders and, 78–80
 corticotropin-releasing factor (CRF) system and, 69–70
 decision making and, 67
 declarative memory and, 58–61
 delayed matching to sample (DMTS) and, 64–65
 delayed nonmatching to sample (DNMTS) and, 64–65
 dog breeds and, 4

dopamine system and, 70–72
dyslexia and, 182–183
embryonic stem (ES) cells and, 54–58
endocannabinoid system and, 72–73
environmental factors and, 80
extinction and, 66, 73
fear conditioning and, 59, 69, 73–75, 78
five-choice serial reaction time task (5–CSRT) and, 65–66
flexibility and, 67
fragile X knockout mice and, 73–74
fruit flies and, 7
galanin system and, 74–75
genetically altered mice and, 51–58, 68–81, 234–235
habituation-dishabituation paradigm and, 64
heritability and, 4
innovation in, 81
instrumental learning and, 64–65
intelligence and, 109
maze-based shifting and, 67
Morris water maze and, 58–60, 63, 69–70, 73–78
neuregulin 1 and, 76–77
new, 81
nicotinic receptors and, 77–78
NMDA receptor and, 76
object recognition and, 63–64
odor span task and, 63
operant conditioning chamber and, 64
opioid system and, 72
oxytocin and, 77
passive and active avoidance and, 60
penetrance and, 51
proline dehydrogenase and, 76
radial maze and, 62–63, 71, 79
rat studies and, 51, 68, 160
reaction time and, 67
recognition memory and, 63–68
response latency and, 66
reversal learning and, 66, 73
schizophrenia 1 and, 76
serotonin and, 150, 152–153
sheep and, 5
shifting and, 67
shock and, 60–61, 66, 68
social discrimination paradigm and, 64
social recognition and, 63–64
social transmission of food preference (STFP) and, 60–61
species differences and, 78–79
targeted gene knockout mice and, 54–58
technical problems and, 79–80
temporal characteristics and, 51
T-maze and, 61–62, 67–68, 70–71, 76
training time and, 80
transgenic mice and, 51–54, 74, 80–81, 234–235
vasopressin and, 77
working memory and, 61–65
Y-maze and, 60
Ankyrin repeat and kinase domain containing 1 (ANKK1), 131
Annett, LE, 59, 66
Anokhin, AP, 135
Ansorge, MS, 133
Anterior cingulate cortex (ACC)
attention and, 125, 130–131, 134–137
genetic dissection of function of, 134–137
profiling candidates and, 135–137
Stroop task and, 125
Anterior cingulate gyrus, 131
Anthropometric Laboratory, 5
Anxiety, 19, 123
alleles and, 150–153
Alzheimer's disease and, 226
association studies and, 146–147
HPA axis function and, 148
MAOA and, 151
serotonin and, 145–153
TPH2 and, 151–152
Aphasia, 228
Apolipoprotein E (APOE)
Alzheimer's disease and, 223, 231–234
cognitive aging and, 161–162, 167–168
intelligence and, 110

Appels, MC, 201
Apraxia, 228
Apud, JA, 249
Arnold, SE, 224
Arriagada, PV, 225
Association studies, xi–xii
 behavioral, 80, 146–149
 candidate gene approaches and, 20, 29, 37–39 (*see also* Candidate gene approach)
 emotion regulation and, 146–147
 fine mapping and, 27
 gene structure and, 8–10
 genome-wide (GWA), 27, 29, 39–43 (*see also* Genome-wide association (GWA))
 Hardy-Weinberg equilibrium (HWE) and, 32–33, 36–38
 imprinting and, 29
 limits of, 149
 linkage, 19–21 (*see also* Linkage analysis)
 McNemar test and, 29
 pooled association and, 107–109
 SNPs and, 21–23, 29
 statistical, 8–10
 structured, 42–43
 threshold disorders and, 17, 19
 two broad categories of, 29
Attention
 animal models and, 135–136
 ANKK1 gene and, 131
 anterior cingulate cortex (ACC) and, 125, 130–131, 134–137
 brain size and, 126
 candidate gene approach and, 126–129
 cell death and, 134
 cholinergic system and, 129
 complex phenotypes and, 17
 COMT and, 127–132
 Continuous Performance Task (CPT) and, 126
 corpus callosum and, 126
 cueing and, 125
 DAT1 and, 130, 133
 delayed response task and, 128
 developmental constraints and, 132–133
 dopamine system and, 127–133
 DRD2 and, 131–132
 DRD4 and, 130
 ECEL1 and, 135–136
 environmental factors and, 132–134
 flexible switching and, 201–202
 frontal cortex and, 126
 gene expression constraints and, 130–132
 heritability and, 125–126
 HOXA1 and, 136–137
 linkage disequilibrium and, 131–132
 MAOA and, 128–130
 MPTP and, 128
 mRNA and, 136
 neural networks and, 124–130
 neuroimaging and, 129–130
 nicotinic receptors and, 129
 norepinepherine system and, 124
 NPPC and, 135
 NXPH3 and, 135–136
 orienting and, 125, 129
 parietal lobe and, 125
 prefrontal cortex and, 129
 prepulse inhibition and, 132
 raphe nuclei and, 130–131
 reaction time and, 128
 reliability and, 125–126
 schizophrenia and, 123, 127, 135, 195–196, 200–202
 SDK1 and, 137
 selective, 126
 sensorimotor gating and, 126
 serotonin and, 129–130, 133–134
 sFRP2 and, 135–136
 smooth pursuit eye tracking and, 126
 Span of Apprehension task and, 126
 Spontaneous Selective Attention Task and, 126
 Stroop task and, 125
 superior temporal lobe and, 125
 TAC1 and, 135–136
 TaqIA polymorphism and, 131–132

TPH and, 133
twin studies and, 126
Attentional set shifting, 67, 126
Attention-deficit/hyperactivity disorder (ADHD), 109, 123, 127, 183–184
Attention network test (ANT), 125–126, 129
Attention Task, 74, 123
Aubert, J, 40
Auerbach, JG, 133
Aultman, JM, 61
Austin, MC, 131
Australian studies, 108, 110, 168
Autism, 109, 112
Autosomes, 7
Avishai–Eliner, S, 134
Avoidance, 60, 77–78
Axis II diagnostic scale, 17

Baare, WF, 101
Bach, ME, 69
Bacterial artificial chromosome (BAC) clones, 52–53
Baddeley, A, 197
Baker, LA, 103
Bakker, SC, 184
Barnes, CA, 60
Barnes maze, 60, 69
Barnett, JH, 207
Bartels, M, 98
Bartlett, CW, 183
Basolateral amygdala, 68
Bateson, P, 79
Batty, GD, 98
Baunez, C, 65
Bayesian models, 40, 42–43
Beadle, GW, 9
Bearden, CE, 132
Beglopoulos, 136
Behavior
addictive, 70, 123, 147
animal models and, 51–81 (*see also* Animal models)
anxiety and, 19, 123, 145–153, 226
association studies and, 146–149
attention and, 65–66
avoidance and, 60, 77–78
brain-derived neurotrophic factor (BDNF) and, 75–76
brain reaction diversity and, 10–11
calcium/calmodulin-dependent protein kinase II and, 68–69
change in habits, 66
conditioned punishment and, 60–61, 66–68
corticolimbic function and, 145–153
corticotropin-releasing factor (CRF) system and, 69–70
data interpretation and, 80
decision making and, 68
declarative memory and, 58–61
delayed comparison procedures and, 65
dopamine system and, 70–72, 147–148
dyslexia and, 177–186
emotion and, 3 (*see also* Emotion)
endocannabinoid system and, 72–73
environmental effects and, 3–4, 80, 98–101, 105–107
extinction and, 66, 73
extraversion and, 146–147
fear conditioning and, 59, 69, 73–75, 78
five-choice serial reaction time task (5–CSRT) and, 65–66
flexibility and, 67
galanin system and, 74–75
genetically altered mice and, 51–58, 68–81
genetic risk factors and, 3, 123
habituation-dishabituation paradigm and, 64
human diversity in, 3
imprinting and, 12
instrumental learning and, 64–65
knockout mice and, 52, 54–58, 73–74
Morris water maze and, 58–60, 69–70, 73–78
nature/nurture debate and, 3
NEOAC measure and, 17
NMDA and, 76
operant conditioning chamber and, 64
opioid system and, 72

Behavior (cont.)
perseverative, 66
radial maze and, 62–63, 71, 79
reaction time and, 67–68
recognition memory and, 63–68
reversal learning and, 66, 73
schizophrenia and, 76, 195–208 (*see also* Schizophrenia)
serotonin and, 145–153
shifting tasks and, 67
shock and, 60–61, 66, 68
social discrimination paradigm and, 64
T-maze and, 61–62, 67–68, 70–71, 76
transgenic mice and, 51–54
working memory and, 61–65
Bejar, R, 69
Bellini, G, 182
Bender, HU, 15
Bendixen, MH, 169
Benes, FM, 134
Benmoyal-Segal, L, 70
Bennett, DA, 168, 232
Benyamin, B, 98
Berchtold, NC, 171
Beriman, L, 45
Bertolino, A, 248–249
Bertram, L, 233
Beta-amyloid protein, 223–224, 227–228, 232
Betz, UA, 52
Bialystok, E, 159
Bible, 5
Bielsky, IF, 77
Bigos, Kristin L., 145–157
Bilder, RM, 71, 199, 201–203, 246–248
Binet, Alfred, 16
Binomial distribution, 34–35
Biocomputing Platforms Ltd., 39
Bioinformatics. *See also* Neuroimaging
Alzheimer's disease and, 226
data mining algorithms and, 45
DISC1 and, 8
picking genes for study, 19–24
random forest and, 45
serotonin and, 149–153
training set and, 45–46
Bipolar disorder, 19
Bird, TD, 231
Birrel, JM, 67
Black fly, 19
Blackwood, DH, 196
Blakely, RD, 14
Blasi, G, 201
Blier, P, 149
Blindness, 19
Block design test, 168
Blood-oxygen-level-dependent (BOLD) activation, 160, 170
Body mass index, 207
Boehnke, M, 46
Bondi, MW, 168
Bonney, GE, 31
Bontekoe, CJ, 74
Bookheimer, S, 232
Boomsma, DI, 98
Borkenau, P, 103
Bosker, R, 31
Bouchard, TJ, Jr, 98–99
Braff, DL, 126, 197
Brain. *See also* Cognition; Specific structure
aging and, 159–171
Alzheimer's disease and, 221–235
attention and, 65–66, 123–137
axospinous synapses and, 160
dendritic branching and, 160
developmental constraints and, 132–133
environmental factors and, 133–134 (*see also* Environmental factors)
gene expression constraints and, 130–132
pharmacogenetic approaches and, 245–255
plasticity and, 160
schizophrenia and, 195–208 (*see also* Schizophrenia)
Brain-derived neurotrophic factor (BDNF)
Alzheimer's disease and, 223
animal models and, 75–76
bioinformatics and, 15

cognitive aging and, 161, 170
emotional reactivity and, 152
schizophrenia and, 203, 206
Brain Explorer software, 22
Brain size, 126
Brain volume, 101–103
Branchek, TA, 74
Bray, NJ, 251
Breast cancer, 28
Breeding, 4–5, 20, 51, 58, 79, 81
Bretsky, P, 168
Brito, GN, 61
Brito, LS, 61
Broad sense heritability, 30
Bronfenbrenner, U, 185
Brouwers, N, 226
Brown, RM, 128
Brown, VJ, 67
Browne, WJ, 31
Brozoski, TJ, 128
Brunkan, AL, 228–229
Brute-force algorithms, 23
Buchanan, RW, 250
Buckholtz, JW, 199–200
Buhle, J, 200
Bujard, H, 53
Bunsey, M, 61
Burdick, Katherine E.
intelligence and, 111
pharmacogenetics and, 245–255
schizophrenia and, 199–200, 204, 207
Buresova, O, 63
Bush, G, 125, 135
Butcher, LM, 108, 112
Buxbaum, JD, 109
Buyske, S, 108

CA1 region, 63, 76, 160
CA3 region, 160
Caballero, IM, 223
Cadoret, RJ, 185
Calcium/calmodulin-dependent protein kinase II, 52, 68–69
California Verbal Learning Test, 202
Callicott, JH, 197, 199, 204
Callosal sulcus, 134–135
Caloric restriction, 161
Cambridge Examination for Mental Disorders of the Elderly, 228
Cambridge Neuropsychological Test, 199
Campion, D, 225, 228
Candidate gene approach
animal models and, 109
attention and, 126–129
biological plausibility and, 109–110
dyslexia and, 181–183
efficiency of, 37
intelligence and, 109–112
migratory patterns and, 127
neuroimaging and, 129–130
pharmacogenetics and, 246–248
schizophrenia and, 195–208
statistical methods and, 20, 29, 37–39
Canli, T, 123, 133–134, 152
Cannabinoid receptors, 72–73
Cannon, TD, 126, 135, 196, 198, 201–204
Capecchi, MR, 54
Cardinal, RN, 68
Cardno, AG, 195, 198
Carey, G, 148
Carlson, CS, 107
Carroll, JB, 97
Carter, CS, 135, 197
Cases, O, 72
Caspi, A, 124, 129, 134, 150, 153, 185
Castner, SA, 197
Catechol-O-methylfransferase (COMT), 11, 13, 15, 71
attention and, 127–132
cognitive aging and, 168–169
intelligence and, 110–111
personality and, 147
schizophrenia and, 199, 201, 203, 206–207, 248–249, 253–254
Cecchi, C, 229
Ceci, SJ, 185

C. elegans, 161
Centimorgan (cM), 7
Central nervous system (CNS)
 cognitive aging and, 161, 167, 171
 history of genetics and, 4–24
 nicotinic receptors and, 77–78
 schizophrenia and, 206, 249, 251
CERAD cognitive tests, 167–168
Cerebral cortex, 69–70
Cerebrospinal fluid, 69–70
Champtiaux, N, 77
Change in habits, 66
Changeux, JP, 77
Chapman, J, 232
Cheek swabs, 128
Chen, Jingshan, 15, 51–94, 248
Chen, Q, 252
Chen, WJ, 201
Chen, ZY, 75
Cheverud, JMK, 126
Children
 Down's syndrome and, 8, 223, 225, 227–228
 dyslexia and, 177–186
 environmental factors and, 98–99
 Huntington's disease and, 223
 intelligence and, 98–114
 maltreatment effects and, 129
 Rett syndrome (RS) and, 222–223
 twin studies and, 98–101
Childs, B, 15
Chimpanzees, 7
China, 21, 131
Chi–square tests, 33, 37–38
Cholinergic basal forebrain, 74
Cholinergic muscarinic receptor 2 (CHRM2) gene, 111
Cholinergic system, 129
Christensen, K, 101
Christiansen, L, 161
Chromosomes, 6
 Alzheimer's disease and, 221–235
 arm/band identity and, 7
 attention networks and, 126–130
 autosomes and, 7
 bacterial artificial chromosome (BAC) clones and, 52–53
 base pair mismatch and, 8
 candidate gene association studies and, 20, 29, 37–39
 copy number variations (CNVs) and, 11–12
 crossover events and, 8
 disorders from missorting of, 8
 dyslexia and, 181–183
 family-based association test (FBAT) and, 39
 fragile X knockout mice and, 73–74
 gender and, 7
 genome-wide association (GWA) and, 27, 29, 39–43
 homologous, 7–8
 imprinting and, 12
 intelligence and, 108 (*see also* Intelligence)
 linkage analysis and, 27–29, 34–37
 marker statistics and, 27–29, 32–43
 meiosis and, 7–8
 neuroimaging and, 123
 pair exchange and, 7–8
 phase and, 38
 random distribution and, 7
 schizophrenia and, 195–208, 245–255
 sequencing abnormalities and, 8
 structure of, 7
 transmission disequilibrium test (TDT) and, 29, 38–39
 trend tests and, 38
Chudasama, Y, 65, 80
Chumakov, I, 252
Churchill, JD, 133
Cingulated cortex, 59
Cirillo, MA, 202
Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE), 247
Coccaro, EF, 147
Coding
 Alzheimer's disease and, 222–223
 dyslexia and, 179
 enzymes and, 9

functional variations and, 12–16
logistic regression and, 38
phonological, 179
proteins and, 9
statistical association and, 8–10
Cognition
aging and, 159–171
Alzheimer's disease and, 221–235
animal models and, 51–81
association studies and, xi–xiii (*see also* Association studies)
attention and, 65–66, 123–137
change in habits and, 66
complex phenotypes and, 16–19
Darwin's theory and, 5
decision making and, 68
declarative memory and, 58–61
delayed comparison procedures and, 65
developmental constraints and, 132–133
dyslexia and, 177–186
emotion and, 3 (*see also* Emotion)
extinction and, 66, 73
familial personality and, xi (*see also* Family studies)
fear conditioning and, 59, 69, 73–75, 78
flexibility and, 67
gene expression constraints and, 130–132
general cognition factor and, 97–98
genetically altered mice and, 51–58, 68–81
heritability and, 3–4 (*see also* Heritability)
history of genetics and, 4–24
imprinting and, 12, 29
instrumental learning and, 64–65
intelligence and, 97–114
knockout mice and, 52, 54–58, 73–74
Morris water maze and, 58–60, 69–70, 73–78
neuroimaging and, 123–130
operant conditioning chamber and, 64
pharmacogenetics and, 245–255
radial maze and, 62–63, 71, 79
reaction time and, 65–66, 68, 103–105, 128
recognition memory and, 63–68
reversal learning and, 66, 73
schizophrenia and, 195–208 (*see also* Schizophrenia)
shifting tasks and, 67
spatial networks and, 12
speed of information processing and, 103–105
T-maze and, 61–62, 67–68, 70–71, 76
transgenic mice and, 51–54
working memory and, 61–65
Cognitive aging
animal models and, 160–161
APOE and, 161–162, 167–168
axospinous synapses and, 160
BDNF and, 161, 170–171
block design test and, 168
blood oxygen level and, 160, 170
central nervous system and, 161, 167, 171
COMT gene and, 168–169
conceptualizing effects of, 159–160
dementia and, 161
DISC1 gene and, 169
environmental factors and, 159, 161
fluency and, 168–169
Flynn effect and, 160
gender and, 169
longevity and, 160–171
serotonin and, 169–170
SIR2 and, 160
SLC64A and, 169–170
Tower test and, 168
twin studies and, 161, 167, 170
Werner's syndrome and, 161, 169
WRN gene and, 161
Cohen, JD, 137
Collaborative Study on the Genetics of Alcoholism
(COGA), 108–109, 112
Color, 4–6, 43, 65, 125, 179, 221
Comings, DE, 111
Comorbidity, 183–184
Conditional knockout technology, 55–57
Conditional stimulus (CS), 68

Conditioning
 animal models and, 59–61, 64, 66, 68, 72–74
 contextual, 59
 cued, 59
 fear, 59, 69, 73–75, 78
 punishment and, 68
 shock and, 60–61, 66, 68
 Skinner box and, 64
Confidence interval (CI), 44–45
Confounding
 animal models and, 75, 78–80
 pharmacogenetics and, 253–255
 schizophrenia and, 205–206
 statistical methods and, 41
Conklin, HM, 198, 202–203
Conover, JC, 55
Contextual conditioning, 59
Contingency tables, 43–44
Continuous Performance Tasks (CPT), 126
 molecular genetics and, 201–202
 schizophrenia and, 200–202, 204–205
Coon, H, 126
Cope, NA, 182
Copy number variations (CNVs), 11, 14
Corbetta, M, 125
Corder, EH, 231
Cornblatt, BA, 126, 200
Corpus callosum, 126
Cortico-basal degeneration, 223
Corticolimbic function
 affective disorders and, 148
 anxiety and, 145–153
 association studies and, 146–147
 depression and, 145–146
 dopamine system and, 147–148
 neuroimaging and, 145
 personality and, 147–148
 risk assessment and, 145–146, 153
 serotonin and, 145, 147–153
Corticotropin-releasing factor (CRF) system, 69–70
Corvin, Aiden, 195–219
Costa, PJ, 17
Cotman, CW, 171, 249
Coutureau, E, 68
CpG islands, 23
Craik, FIM, 159
Craiu, R, 40
Crawley, JN, 58–59, 64, 78
Cre, 55–56
Crome, L, 227
Crossover events, 8
Cross-trait cross-twin correlation, 102
Crowell, SL, 127
Cryptrochidism, 12
Crystal structures, 22
CTCTAC, 251
Cued conditioning, 59
Cultural transmission, 106
Cummings, Jeffrey L., 222–244
Curtis, ME, 177
Cystic fibrosis, 28
Cytogenetics, 7

D-amino acid oxidase activator (DAOA), 195, 199, 201, 204–208, 252
Darwin, Charles, 5
Databases, 10, 20, 22–23
Data integration, xi
Data mining algorithms, 45
David, SP, 150, 153
Davidson, MC, 129
Davignon, J, 231
Daw, EW, 233
dbSNP, 10
D-cycloserine, 250
Deary, Ian J.
 cognitive aging and, 162, 168–169
 intelligence and, 97–121
Decision making, 68
Declarative memory, 58–61, 202–203
DeFries, JC, 179, 182
de Geus, Edo JC, 97–121
Delay discounting, 68
Delayed comparison procedures, 65

Delayed matching to sample (DMTS) tasks, 64–65
Delayed nonmatching to sample (DNMTS) tasks, 64–65
Deletions, 8, 11–12
Delta measure, 33–34
δ-opioid receptor, 72
Dementia. *See* Alzheimer's disease
Demonet, JF, 181
Demonstrator mouse, 61
de Montigny, C, 149
Dempster, E, 170, 203
Dendrites, 160
Depression
 Alzheimer's disease and, 226
 corticolimbic function and, 145–146
 HPA axis function and, 148
 major, 19
 manic, 146
 serotonin and, 145–153
De Quervain, DJ, 204
Descarries, L, 128, 130
D'Esposito, M, 160
Detera-Wadleigh, SD, 252
Detterman, DK, 97
Developmental neurobiology, 177–186
Devlin, B, 33, 43
Diabetes, 4, 19, 207
Diagnostic and Statistical Manual of Mental Disorders, 17, 223, 253
Diamond, A, 71
Dias, R, 66
Diaz-Asper, CM, 161
Diaz-Olavarrieta, C, 230
Dick, DM, 108–109, 111
Dickens, WT, 106
Digging, 67
Dinucleotide repeats, 11
Dinwiddie, SH, 124
Discourse comprehension, 178–181
Disease. *See also* Specific type
 chi–square tests and, 33, 37–38
 corticolimbic function and, 145–153
 family studies and, 29–31 (*see also* Family studies)
 genome-wide association (GWA) and, 27, 29, 39–43
 monogenic genes and, 28
 multiplex families and, 28
 neuroimaging and, 123–124
 random-effect logistic models and, 31
Disequilibrium (LD), 21
Disrupted in schizophrenia 1 (DISC1)
 animal models and, 76, 79
 cognitive aging and, 169
 schizophrenia and, 8, 76, 79, 169, 195–196, 199, 204–206, 208, 253
Dizygotic (DZ) twins. *See also* Twin studies
 attention and, 126
 cognitive aging and, 161, 167, 169
 intelligence and, 99, 102–106
 schizophrenia and, 198, 203
 statistical genetics and, 28, 30
DNA (deoxyribonucleic acid), xii
 Alzheimer's disease and, 221
 attention and, 126–130
 base pair mismatch and, 8
 chromosomes and, 7 (*see also* Chromosomes)
 copy number variations (CNVs) and, 11–12
 dinucleotide repeats and, 11
 ease of sampling and, 245–246
 epigenetic function control and, 12
 exons and, 10
 functional variation effects and, 12–16
 human genome project and, 9–10
 imprinting and, 12
 inducer sites and, 9
 inhibitor sites and, 9
 knockout technology and, 52, 54–58, 73–74
 linkage studies and, 19–21 (*see also* Linkage studies)
 marker statistics and, 27–29, 32–43
 mice and, 80
 pooled association and, 107–109
 sequencing abnormalities and, 8
 splicing and, 10

DNA (cont.)
statistical association and, 8–10
transcription phase and, 13–14
variable number tandem repeats (VNTRs) and, 11
variation principles of, 10–12
whole genome approach to intelligence and, 107–109
Dobkin, C, 74
Dodart, JC, 134
Dogs, 4–5
Dominant traits, 6, 43
Donohoe, Gary, 195–219, 252–252
Dopamine system, 11
animal models and, 70–72
attention and, 127–130, 133
extraversion and, 146–147
intelligence and, 111
personality and, 147–148
pharmacogenetics and, 248–249
schizophrenia and, 127, 199, 248–249, 254–255
Doran, M, 223
Dorsolateral prefrontal cortex (DLPFC), 128
Dorus, S, 109
Down's syndrome, 8, 223, 225, 227–228
DRD2 gene, 131–132
DRD4 gene, 130
Drosophila, 161
Drug resistance, 56–57
D-serine, 250, 252
Dudbridge, F, 40
Duncan, GE, 76
Duplications, 8, 11–12
Durston, S, 123, 130
Dysbindin
intelligence and, 111–112
schizophrenia and, 195, 199, 201, 206, 208, 250–252
Dyslexia
ADHD and, 183–184
animal models and, 182–183
candidate gene approach and, 181–183
cognitive dissection of, 177–181
comorbidity and, 183–184
defining, 178
discourse comprehension and, 178–181
genetic loci and, 179–181
G x E interactions and, 184–186
G x G interactions and, 184–186
language impairment (LI) and, 183
linkage analysis and, 185–186
listening comprehension and, 178–181
LOD scores and, 183–184
orthographic coding and, 179
phonological awareness (PA) and, 179
phonological coding and, 179
rapid serial naming (RSN) and, 179, 184
reading comprehension and, 177–181, 185–186
risk loci and, 183–184
speech sound disorder (SSD) and, 183–186
syntax and, 179

Ebstein, R, 147
Eckert, M, 181
Edwards-Lee, T, 226
Edwards syndrome, 8
Effort-based decision-making, 68
Efron, B, 40
Egan, MF, 11, 15
animal models and, 71
attention and, 127, 129, 131
cognitive aging and, 170
intelligence and, 102, 170
schizophrenia and, 197, 199, 201–204, 248, 252
Eggs, 7–8
Eichenbaum, H, 59, 61
Eley, TC, 185
Elgersma, Y, 69
El-ghundi, M, 70
Elston, RC, 37
Embryonic stem (ES) cells, 54–58
Emotion, 3
affective disorders and, 148–153
anxiety and, 19, 123, 145–153, 226

brain reaction diversity and, 10–11
corticolimbic function and, 145–153
depression and, 19, 145–146, 148, 226
DISC1 and, 8
dopamine system and, 147–148
enzymes and, 151–152
extraversion and, 146–147
HPA axis function and, 148
serotonin and, 145–153
ENCylopedia Of DNA Elements (ENCODE), 10
Endocannabinoid system, 72–73
Endothelin converting enzyme-like 1 (ECEL1), 135–136
Enolase, 52
Environmental factors, 9, 11
animal models and, 80
attention and, 132–134
cognitive aging and, 159, 161
dyslexia and, 184–186
epistasis and, 43–46
familial aggregation studies and, 28
gene-gene interaction and, 43–46
G x E interactions and, 105–107
intelligence and, 98–101, 105–107
rGE correlations and, 105–107
statistical genetics and, 27–47
training set and, 45–46
Enzymes. *See also* Specific enzyme
Alzheimer's disease and, 228–229, 233
animal models and, 71–72
attention and, 127–128, 132, 135–136
emotion and, 151–152
functional variations and, 14–15
gene coding and, 9
reaction sites and, 15
schizophrenia and, 199, 248
Epigenetic control, 12
Epistasis
emotion and, 153
schizophrenia and, 206–207, 254
statistical genetics and, 43–46
Equations
full model, 43
interclass correlation coefficient (ICC), 31
LD measure delta, 33
LOD score, 34
Pearson's chi–square test, 33
recombination likelihood, 34–35
reduced model, 43
Erlenmeyer-Kimling, L, 196
Ethical issues, 124
Eukaryotic genes, 52
Evans, PD, 109–110
Evenden, JL, 66, 68
Evocative rGE, 106
Evolution, theory of, 5, 10, 80, 127
Ewens, WJ, 38
Exons, 9–10
Extinction, 66, 73
Extraversion, 146–147
Eysenck, Hans, 17, 103
Ezquerra, M, 231

Fallgatter, A, 200
False discover rate (FDR), 40
Familial aggregation, 27–28, 30
Familial relative risk, 31
Family-based association test (FBAT), 39
Family studies
Alzheimer's disease and, 224–226
association studies and, 29 (*see also* Association studies)
component determination and, 30–32
environmental factors and, 105–107
Fisher's exact test and, 29
heritability and, 98–101 (*see also* Heritability)
imprinting and, 12, 29
intelligence and, 98–114
interclass correlation coefficient (ICC) and, 30–31
linkage analysis and, 34–37
LOD score and, 34–36
McNemar test and, 29
Pearson test and, 29
schizophrenia and, 192, 196, 198, 200–205, 246, 248–249

Family studies (cont.)
SES analysis and, 105
transmission disequilibrium test (TDT) and, 29
twin studies and, 202–203 (*see also* Twin studies)
Fan, Jin, 123–144, 199, 248
Fanselow, MS, 59
Faraone, SV, 201, 203
Farlow, M, 226
Fat mass and obesity (FTO) gene, 207
Fear conditioning, 59, 69, 73–75, 78
Fenton, WS, 123
Fernandez, G, 202
Fine mapping, 27
Finkel, D, 99, 167
Finnish twin register, 198
Fisher, PM, 150
Fisher, R, 17
Fisher, SE, 179, 182
Fisher's exact test, 29, 33
Five-choice serial reaction time task (5–CSRT), 65–66
5′ end site, 9
Floresco, SB, 63, 67
Flory, JD, 168
Fluency, 168–169
Flynn, JR, 106
Flynn effect, 160
FMRP, 73–74
Food
animal models and, 60–63, 66, 74, 79–80
caloric restriction and, 161
social transmission of food preference (STFP) and, 60–61
Footshock, 60–61
Forbes, Erika E., 145–157
Forrest, D, 55
Forss-Petter, S, 52
Fossella, John, 123–144
Fox, HC, 229–230
Fradley, RL, 76
Fragile X protein, 73–74, 133
Francks, C, 182
Frangou, S, 195
Franke, P, 201
Frankland, PW, 69
Frayling, TM, 207
Freedman, R, 197
Freimer, N, 148–149
Frick, KM, 78
Frontal cortex, 126, 199
Fruit flies, 7
Fry, AF, 103
Full model, 43–44
Functional magnetic resonance imaging (fMRI)
anxiety and, 150–152
attention and, 124–125, 129
bioinformatics and, 23
emotion and, 145

Gabrieli, JDE, 160
Galaburda, AM, 182
Galanin (GAL), 52, 74–75
Gallagher, M, 160
Galton, CJ, 223
Galton, Francis, 3, 5, 103
Gamboa, R, 231
Gametes, 8
Gan, L, 71
Garner, JP, 67
Garpenstrand, H, 150
Gasperoni, T, 198
Gauderman, WJ, 46
Gaussian distribution, 16–17
Gayan, J, 179, 183
Gender
Alzheimer's disease and, 230, 232
cognitive aging and, 169
intelligence and, 102
"Gene Atlas of the Mouse and Human Protein-Encoding Transcriptomes, A" (Su), 136
Gene Expression Omnibus (GEO), 136
Gene-gene interactions, 43–46
General cognition factor, 97–98

Genes
coding studies of, 8–10
defining, 6
enzymes and, 9
epigenetic control and, 12
eukaryotic, 52
exons and, 9
function of, 8–10, 12–16
introns and, 9
neuropsychological studies and, 19–24
proteins and, 9
statistical association and, 8–10
structure of, 8–10
transgene and, 51–54
Genetic amplification, 98
Genetic distance, 7
Genetics
adoption studies and, xi, 98–100
Alzheimer's disease and, 221–235
animal models and, 51–81
brief history of, 4–24
chromosomes and, 6–8 (*see also* Chromosomes)
cognitive aging and, 159–171
copy number variations (CNVs) and, 11–12
corticolimbic function and, 145–153
Darwin on, 5
databases for, 10
defined, 3
dinucleotide repeats and, 11
dominant/recessive traits and, 6, 43 (*see also* Traits)
dyslexia and, 177–186
embryonic stem (ES) cells and, 54–58
environmental factors and, 9 (*see also* Environmental factors)
epigenetic function control and, 12
ethics and, 125
familial personality and, xi (*see also* Family studies)
Galton on, 5–6
genetically altered mice and, 51–58, 68–81
height and, 4
high-throughput genotyping platforms and, 39
human genome project and, 9–10
hybrids and, 5–6
intelligence and, 97–114
International HAPMAP Project and, 21
linkage studies and, 19–21 (*see also* Linkage studies)
longevity and, 160–171
meiosis and, 6–8
Mendel and, 5–6
migratory patterns and, 127
neuroimaging and, 23, 102–103, 123–124
pharmacogenetics and, 245–255
principles of variation and, 10–16
privacy and, 125
Punnet square and, 6
schizophrenia and, 195–208, 245–255
selective breeding and, 4–5
splicing and, 10
statistical methods in, 27–47
transcription phase and, 13–14
variable number tandem repeats (VNTRs) and, 11
Gene trapped knockout mouse technology, 56
Geng, Y, 57
Genome-wide association (GWA), 27, *29*, 37
Australian study and, 108
case-control, 39
confounding and, 41
Dutch study and, 108
false discovery rate (FDR) and, 40
family-based, 39
genomic control and, 42–43
haplotypes and, 39
high-throughput platforms and, 39
imputation and, 39
intelligence and, 107–109
linkage disequilibrium and, 39–40
multiple testing and, 39–41
permutation procedures and, 40
pooled association and, 107–109
population stratification and, 41, 43
p values and, 40

Genome-wide association (cont.)
q values and, 40
replication and, 40
schizophrenia and, 253–254
structured association and, 42–43
subpopulation data and, 41–43
training set and, 45–46
Genomic control, 42–43
Gerlai, R, 77
Germany, 231
Gerstein, MB, 9–10, 23
Geschwind, N, 230
Geyer, MA, 126
Giese, KP, 69
Gilbert, SL, 109
Giovagnoli, AR, 231
Glahn, DC, 198, 245–255
Glatt, CE, 148–149
Glickstein, SB, 70
Gliosis, 134
Glutamate, 201, 249–253
Glycine, 250
Goate, A, 225, 228–229
Goghari, VM, 135
Gogos, JA, 71, 132
Goldberg, Terry E.
animal models and, 71
attention and, 123
cognitive aging and, 159–174
pharmacogenetics and, 247
schizophrenia genetics and, 195–219, 252
Goldman-Rakic, PS, 128, 197, 249
Gomez-Isla, T, 224–225
Gong, S, 52
Gong, Y, 224
Gonzalez-Alegre, P, 223
Good, KP, 196
Gordon, JW, 52
Gossen, M, 53
Gosso, MF, 111
Gottesman, II, 146, 195–198
Gottfredson, LS, 97
Gough, PB, 178
Gould, TD, 197
Gourovitch, ML, 202–203
Greely, HT, 234
Green, MF, 61, 196, 246
Greenwood, TA, 129, 168
Gu, H, 55
Guarente, L, 161
Gureje, O, 231
Guttman, R, 101
G x E interactions, 105–107, 184–186
G x G interactions, 184–186

Habituation-dishabituation paradigm, 64
Hagberg, B, 222
Hahn, MK, 14
Haile, CN, 70
Hale, S, 103
Hall, J, 200
Hallmayer, JF, 201, 203, 251
Hamilton, RL, 224
Handler, M, 229
Hannula-Jouppi, K, 182
Haplotypes
attention and, 131–132
bioinformatics and, 21
dyslexia and, 182
genome-wide association (GWA) and, 39
schizophrenia and, 200, 204–205, 250–252
statistical genetics and, 33, 36, 38–39
HAPMAP sites, 21, 23, 131–132
Hardy-Weinberg equilibrium (HWE), 32–33, 36–38
Harhangi, BS, 232
Hariri, Ahmad R., 131, 133, 145–157, 170, 203
Harm, MW, 179
Harris, SE, 111, 170
Harrison, PJ, 123
Harvey, PD, 247
Harwood, DG, 231
Haseman, JK, 37
Haseman-Elston regression, 37
Hatakeyama, S, 184
Hauber, W, 68

Hay, DA, 100
Hayashi, K, 137
Hedden, T, 160
Hedgehog signaling, 137
Height, 16
Heinrichs, RW, 69, 201
Heinz, A, 134
Hemideletion, 11
Hen, R, 148
Hendrich, B, 223
Hennah, W, 204, 207
Heresco-Levy, U, 250
Heritability, 3
 adoption studies and, 98–100
 animals and, 4
 attention networks and, 125–126
 brain volume and, 101–103
 broad sense, 27, 30
 cognitive aging and, 161–162, 167
 component determination and, 30
 Darwin's theory and, 5
 dominant/recessive traits and, 6, 43 (*see also* Traits)
 family-based association test (FBAT) and, 39 (*see also* Family studies)
 genome-wide association (GWA) and, 27, 29, 39–43
 hybrids and, 5–6
 intelligence and, 97–105, 111–112
 longevity and, 171
 marker statistics and, 32–34
 Mendel and, 5–6
 narrow sense, 27, 30, 32
 plants and, 4
 Punnet square and, 6
 schizophrenia and, 192, 198, 201–205
 selective breeding and, 5
 statistical genetics and, 27–47
 twin studies and, 98–101 (*see also* Twin studies)
 variance component and, 27
Herringa, RJ, 69
Heterozygotic twins, 32, 38, 69, 71, 75, 77, 111
Heyser, CJ, 72
Higgins, GA, 65
Hiltunen, M, 233
Hippocampus, 23
 calanin system and, 74
 conditioning and, 59
 DISC1 and, 8
 food and, 61
 galanin system and, 74–75
 learning and, 69
 Morris water maze and, 63
 recognition memory and, 64
 serotonin and, 153
 transgenic mice and, 52–53
 working memory and, 63
Ho, HZ, 103
Holland, F, 228
Holmes, A, 150, 153
Holmes, C, 70
Holsboer, F, 75
Holter, SM, 73
Holtzman, DM, 232
Homozygotic twins
 animal models and, 51, 75, 77, 79
 attention and, 136
 cognitive aging and, 169–171
 intelligence and, 111
 schizophrenia and, 204, 248–249
 statistical genetics and, 32
Hoover, DM, 178, 183
Hori, Y, 226
HOXA1, 136–137
Hsiung, GY, 184
Hulshoff Pol, 101–103
Human Gene Nomenclature Committee, 182
Human genome, 9
 brain reaction diversity and, 10–11
 complex phenotypes and, 16–19
 estimated number of genes in, 16
 intelligence and, 107–109, 112–114
 mice and, 54, 80
 sequencing costs and, 24

Humanized transgenic mouse technology, 54
Hunter, JE, 98
Huntington's disease, 223
Hybrids, 5–7
Hyman, BT, 123
Hyperphagia, 12
Hypothalamic-pituitary-adrenal (HPA) axis function, 148

Identical by descent (IBD) alleles, 30, 36–37
Imprinting, 12, 29
Inducer sites, 9
Inductible transgenic mouse technology, 53–54
Inheritance, 3
 chromosomes and, 6–8
 crossover events and, 8
 eye color and, 5
 heritability concept and, 3–4 (*see also* Heritability)
 Jacob/Laban account and, 5
 linkage analysis and, 27–29, 34–37
 meiosis and, 6–8
 Mendel and, 5–6
 pair exchange and, 7–8
Inhibitor sites, 9, 12
Inlow, JK, 109
Insertion, 8
 bacterial artificial chromosome (BAC) clones and, 52–53
 drug resistance and, 56–57
 genetically altered mice and, 51–58, 68–81
Inspection time, 104
Instrumental learning, 64–65
Insulin degrading enzyme (IDE), 233
Intelligence, 16–17
 academic success and, 98
 ADHD and, 109
 adoption studies and, 98–100
 aging and, 98–101, 110, 159–171
 Alzheimer's disease and, 223–225
 animal models and, 109
 brain functioning and, 103–105
 brain volume and, 101–103
 candidate gene approach and, 109–112
 children and, 98–114
 CHRM2 gene and, 111
 COMT gent and, 110–111
 crystallized, 167
 definition of, 97
 DTNBP1 gene and, 111–112
 dyslexia and, 177–186
 environmental factors and, 98–101, 105–107
 factor analysis and, 97
 family studies and, 98–114
 gender and, 102
 general cognition factor and, 97–98
 genetic amplification and, 98
 genome-wide association (GWA) and, 107–109
 G x E interactions and, 105–107
 heritability and, 98–105, 112
 human genome and, 112–114
 individual differences in, 97
 information processing speed and, 103–105, 167
 inspection time and, 104
 job success and, 98
 linkage analysis and, 108–109
 longevity and, 98
 molecular genetics and, 107–112
 multivariate studies of, 101–105
 performance, 102
 phenotypic correlation and, 104–107
 pooled association and, 107–109
 premorbid, 251
 reaction time and, 103–105
 rGE correlations and, 105–107
 schizophrenia and, 112, 196–197, 200, 251–252, 254
 SNAP-25 gene and, 111–112
 socioeconomic status and, 98
 structural equation modeling and, 102
 twin studies and, 98–106, 111
 verbal, 102
 Wechsler Adult Intelligence Scale (WAIS), 27, 102, 104, 199–200

whole genome approach and, 107–109
Wisconsin Card Sorting Test, 67, 128, 199, 202, 205, 230
Interaction OR, 44
Interclass correlation coefficient (ICC), 30–31
International HAPMAP Project, 21, 23, 131–132
Intertrial delay, 61
Intertrial intervals (ITIs), 66
Intratrial delay, 61
Introns, 9, 57
Inversions, 8
Inverted-U functional response curve, 249
Iowa Gambling Task, 68
IQ tests, 16–17, 97. *See also* Intelligence
academic success and, 98
age and, 98
environmental factors and, 105
Flynn effect and, 160
job success and, 98
literature on, 98
longevity and, 98
multivariate studies of, 101–105
phenotypic correlations and, 104
Raven's Matrices and, 103–104
reaction time and, 104–105
singletons and, 101
twin studies and, 98–101
Irish study, 252
Iversen, SD, 66
Izquierdo, A, 65

Jacob (Biblical person), 5
Jacoby, AS, 74
Jaffee, SR, 124
Jamot, L, 72
Jang, CG, 72
Janka, Z, 201
Japan, 21, 131, 226
Javitt, DC, 197
Jensen, M, 102
Johannsen, Wilhelm, 6
Jones, KR, 65–66
Joober, R, 71, 199
Jordan, BD, 232
Jorm, A, 168
Jung, MY, 70

Kachiwala, SJ, 169
Kamil, AC, 79
Kamprath, K, 73
Karayiorgou, M, 132
Karlinsky, H, 226
Karmiloff-Smith, A, 123, 133
Katsanis, J, 126
Keefe, RS, 201, 246–247
Keenan, JM, 178
Keilp, JG, 200
Kellendonk, C, 62, 70
Kempf, Lucas, 3–26
Kendler, KS, 148, 150
Kennedy, AM, 229
Kenyon, C, 161
Keri, S, 198, 201
Kernie, SG, 75
Ketamine, 249
Kiely, JL, 100
Killcross, AS, 68
Kim, JJ, 59
Kimmel, G, 40
Kinney, JW, 74
Klotho, 110, 169
Knock-in mouse technology, 57–58, 69
Knockout mice, 52, 54–58, 73–74, 182–183
Kooy, RF, 73
κ-opioid receptor (KOR), 72
Kovas, Y, 108, 112, 208
Kovelowski, CJ, 128
Krabbendam, L, 198
Krawczak, M, 46
Kremen, WS, 185

Laban (Biblical person), 5
Lange, C, 46
Lange, KW, 128
Language impairment (LI), 183
Laplante, F, 74

LaRusse, S, 234
Laurent, A, 201
Lavretsky, H, 167
Ledent, C, 72
LeDoux, J, 59
Lefly, D, 179
Lencz, T, 246
Leonardo, ED, 148
Lesch, KP, 149–150
LeTurco, Joseph, 182
Leukemia, 54
Levy, E, 197, 226
Lewontin, R, 34, 185
Li, Y, 55
Lichtman, AH, 73
Likelihood ratio test (LRT), 43, 45
Lin, DY, 40
Linkage analysis, 19–21. *See also* Family studies
 affected sib pairs (ASP) and, 36
 allele-sharing values and, 29
 Alzheimer's disease and, 225–226
 autism and, 109
 dyslexia and, 185–186
 Hasemen-Elston regression and, 37
 intelligence and, 108–109
 LOD score and, 34–36, 46, 183–184
 molecular biology techniques and, 34
 monogenic genes and, 28
 multiplex families and, 28
 nonparametric, 27–29
 parametric, 27–28, 36
 pedigree structure and, 34–35
 quantitative traits and, 37
 relative pair method and, 36
 schizophrenia and, 198–200, 203
 Solar software and, 37
 statistical genetics and, 27–29, 34–37
 within-family association and, 34–36
Linkage disequilibrium (LD), 15–16, 21
 attention and, 131–132
 candidate gene approach and, 109
 genome-wide association (GWA) and, 39–40
 intelligence and, 109–110
 permutation procedures and, 40
 statistical genetics and, 33–34, 38
Linnarson, S, 75
Lippa, CF, 226, 229, 231
Listening comprehension, 178–181
Liu, L, 249
Local FDR, 40
Local Global Task, 201–202
LOD score, 34–36, 46, 183–184
Loehlin, JC, 99
Logistic regression, 31–32, 38, 40, 170
Logue, SF, 59
Lohmueller, J, 127–128
Longevity
 APOE and, 167–168
 BDNF and, 170–171
 caloric restriction and, 161
 cognitive aging and, 160–171
 COMT and, 168–169
 SLC64A and, 169–170
 Werner's syndrome and, 161, 169
Loo, SK, 184
Lopera, F, 229
Lothian birth cohort (LBC), 110
Lowenberg, K, 225
LoxP element, 55–56
Luciano, M, 99, 104, 108
Lucki, I, 149–150
Luellen, BA, 152
Lynch, M, 32
Lyons, MJ, 75

McCarron, MO, 232
McClearn, GE, 99
McCrae, RR, 17
McCrory, E, 181
McDaniel, MA, 102
MacDonald, AW, 125, 197
McDonald, C, 195
McDonald, RJ, 63
McEwen, BS, 134
McGrath, Lauren M., 177–193
McGue, M, 98

McKeith, IG, 224
MacLullich, AMJ, 102
McMahon, RP, 252
McNemar method, 29
Macular degeneration, 19
Magnetic resonance imaging (MRI), 23, 102–103, 123–124, 130
Magyar, O, 67
Mahley, RW, 233
Maier, SF, 151
Major depression, 19
Malhotra, Anil K., 71, 199, 245–249
Manic depression, 146
Mann, JJ, 225, 227
Manuck, SB, 148, 150
Marchini, J, 39, 45
Marino, C, 182
Marjaux, E, 229
Marker statistics, 123
 affected sib pairs (ASP) and, 36
 allele frequency and, 32
 candidate gene association studies and, 37–39
 Delta measure and, 33–34
 genome-wide association (GWA) and, 27, 29, 39–43
 Hardy-Weinberg equilibrium and, 32–33
 high-throughput genotyping platforms and, 39
 linkage analysis and, 27–29, 33–37
 LOD score and, 34–36
 phenotypes and, 27, 29, 32–34, 39–43
 transmission disequilibrium test (TDT) and, 29, 38–39
Marrocco, RT, 124, 129
Marsicano, G, 72
Martin, P, 79
Martinowich, K, 223
Mattay, Venkata S., 159–174, 249
Mauldin, JE, 79
Mayeux, R, 234
Mayford, M, 52, 54, 60, 69
Mazes
 Barnes, 60, 69
 Morris water, 58–60, 69–70, 73–78
 radial, 62–63, 71, 75–76, 79
 shifting task and, 67
 T, 61–62, 67–68, 70–71, 76
 technical problems and, 79
 Y, 60
Medial frontal cortex, 67
Medial temporal lobe, 59
Mega, MS, 226
Mehmet, H, 134
Meiosis, 6–8
Mekel-Bobrov, N, 110
Membrane metallo-endopeptidase (MME), 136
Memory
 Alzheimer's disease and, 221–235
 APOE and, 161–162, 167–168
 aversive, 73
 brain volume and, 101–103
 calcium/calmodulin-dependent protein kinase II and, 52, 68–69
 cognitive aging and, 159–171
 complex phenotypes and, 16–17
 declarative, 58–61, 202–203
 dopamine system and, 11, 70–72
 endocannabinoid system and, 72–73
 episodic, 195, 202
 extinction and, 73
 gene coding and, 8–9
 molecular genetics and, 203–205
 nicotinic receptors and, 77–78
 olfactory, 74
 postural mediation and, 80
 prefrontal cortex (PFC) and, 61–62
 recall and, 203–205
 recognition, 63–68
 schizophrenia and, 197–205, 248–249
 statistical association and, 8
 storage subsystems and, 197
 verbal, 203–204
 visual, 203
 working, 61–65, 195, 197–200, 205, 248–249
Mendel, Gregor, 5–6
Mendelian traits, 6, 19
Meng, H, 182

Mensah, FK, 38
Mental retardation, 8, 12
 attention and, 132, 136
 dyslexia and, 179
 fragile X protein and, 73–74, 133
 intelligence and, 109
Mental retardation syndrome, 228
Mesulam, MM, 124
Methuselah, 161
Methyl-CpG-binding protein (MeCP2), 222–223
Meyer-Lindenberg, A, 12, 130, 133–134, 161, 196, 199–201, 208
Meyers, EN, 56
Mice, 43
 age-dependent performance deterioration and, 78
 attention and, 65–66
 avoidance and, 60, 77–78
 Barnes maze and, 60, 69
 brain-derived neurotrophic factor (BDNF), 75–76
 breeding and, 51
 calcium/calmodulin-dependent protein kinase II and, 52, 68–69
 cognitive aging and, 160–161
 conditioned punishment and, 68
 confounding and, 75, 78–80
 corticotropin-releasing factor (CRF) system and, 69–70
 decision making and, 68
 declarative memory and, 58–61
 delayed matching to sample (DMTS) and, 64–65
 delayed nonmatching to sample (DNMTS) and, 64–65
 demonstrator, 61
 dopamine system and, 70–72
 drug resistance and, 56–57
 embryonic stem (ES) cells and, 54–58
 endocannabinoid system and, 72–73
 environmental factors and, 80
 extinction and, 66
 fear conditioning and, 59, 69, 73–75, 78
 flexibility and, 67
 fragile X, 73–74
 galanin system and, 74–75
 genetically altered, 51–58, 68–81
 habituation-dishabituation paradigm and, 64
 instrumental learning and, 64–65
 knock-in, 57–58
 knockout, 52, 54–58, 73–74, 182–183
 Morris water maze and, 58–60, 69–70, 73–78
 neuregulin 1 and, 76–77
 nicotinic receptors and, 77–78
 NMDA receptor and, 76
 object recognition and, 63–64
 odor span task and, 63
 opioid system and, 72
 oxytocin and, 76–77
 proline dehydrogenase and, 76
 radial maze and, 62–63, 71, 75–76, 79
 rat studies and, 51
 reaction time and, 68
 recognition memory and, 63–68
 reversal learning and, 66, 73
 schizophrenia 1 and, 76
 shifting and, 67
 social discrimination paradigm and, 64
 social recognition and, 63–64, 77
 social transmission of food preference (STFP) and, 60–61
 species effects and, 78–79
 T-maze and, 61–62, 67–68, 70–71, 76
 training time and, 80
 transgenic, 51–54, 74, 80–81, 234–235
 vasopressin and, 76–77
 working memory and, 61–65
 Y-maze and, 60
Microcephalin (MCPH1), 110
MicroRNAs, 14
Migrant studies, 27–28, 127
Miksys, SL, 54
Miller, S, 69
Milner, B, 202
Mineur, YS, 73
Minichiello, L, 76

Mini–Mental state Examination (MMSE), 230
Mini Mental task, 169
Minnesota Study of Twins Reared Apart, 99
Mishkin, M, 66
Mismatch negativity, 197
Mobini, S, 68
ModBase, 22
Moffitt, TE, 153
Moghaddam, B, 61
Mohn, AR, 76
Moldin, SO, 146
Molecular genetics
 Continuous Performance Tasks (CPT) and, 200–202
 dyslexia and, 177–186
 intelligence and, 107–112
 memory recall and, 203–205
 schizophrenia and, 201–205
 whole genome approach and, 107–109
Monoamine oxidase a (MAOA), 128–130, 151
Monoamine oxidase (MAO), 72
Monogenic disease genes, 28
Monozygotic (MZ) twins
 attention and, 126
 cognitive aging and, 161, 167
 intelligence and, 99, 102–106
 schizophrenia and, 198, 202–203
 statistical genetics and, 28, 30
Monteggia, LM, 75
Montkowski, A, 75
Morgan, Thomas, 7
Morris, RG, 59
Morris water maze, 58–60, 69–70, 73–78
Morrow, BA, 64
Motor skills
 animal models and, 58–60, 70
 Alzheimer's disease and, 222–224
 attention and, 136
 complex phenotypes and, 17
 schizophrenia and, 255
Moulard, B, 232
MPTP, 128
mRNA (messenger RNA), 9, 22
 attention and, 136
 corticotropin-releasing factor (CRF) system and, 69–70
 functional variation effects and, 12–16
Muir, JL, 65, 80
Mullan, M, 226
Muller-Myhsok, B, 40
Multiple sclerosis, 19
Multiple testing, 39–41
Multiplex families, 28
Multivariate studies, 101–105
Mumby, DG, 64
Munafo, MR, 148–149, 151
μ-opioid receptor (MOR), 72
Murphy, DL, 149
Mutsuddi, M, 205
Myles-Worsley, M, 126, 198

Nachman, MW, 127
Nackley, AG, 13
Narrow sense heritability, 30, 32
Nathan, BP, 101, 233
Nation, K, 178
National Collaborative Perinatal Project, 105
National Institute of Mental Health, 247
National Institutes of Health (NIH), 58
Natriuretic peptide precursor C (NPPC), 135–136
N-back task, 201, 206, 248, 254
NCBI cd3d structures, 22
Need, AC, 69
Neisser, U, 98, 185
NEOAC (Neuroticism, Extroversion, Openness to Experience,
 Agreeableness, and Conscientiousness), 17
Nestin, 52
Netherlands, 108, 110–111
Neubauer, AC, 104
Neural networks
 attention and, 123–137
 neuroimaging and, 123–124
 Stroop task and, 125

Neural nicotinic cholinergic receptor (CHRNA4), 129
Neuregulin 1 (NRG1), 13–14, 76–77, 195, 200, 206, 253
Neurexophilin 3 (NXPH3), 135–136
Neurofibrillary triangles (NFTs), 223–225, 227
Neuroimaging
 anterior cingulate cortex (ACC) and, 125, 130–131, 134–137
 attention networks and, 129–130
 candidate gene approach and, 129–130
 chromosomes and, 123
 corticolimbic function and, 145
 false positives/negatives and, 124
 functional magnetic resonance imaging (fMRI) and, 23, 124–125, 129, 145, 150–152
 magnetic resonance imaging (MRI) and, 23, 102–103, 123–124, 130
 positron emission tomography (PET) and, 150, 153
 schizophrenia and, 195
 serotonin and, 145
 statistical genetics and, 123–124
Neuropsychiatric genetics
 Alzheimer's disease and, 221–235
 animal models and, 51–81
 brain-derived neurotrophic factor (BDNF) and, 75–76
 calcium/calmodulin-dependent protein kinase II and, 52, 68–69
 candidate gene association studies and, 37–39 (*see also* Candidate gene approach)
 component determination and, 30–32
 corticotropin-releasing factor (CRF) system and, 69–70
 dopamine system and, 70–72
 endocannabinoid system and, 72–73
 environmental factors and, 43–46
 epistasis and, 43–46
 familial correlation and, 30–31
 family-based association test (FBAT) and, 39 (*see also* Family studies)
 fear conditioning and, 59, 69, 73–75, 78
 Fisher's exact test and, 29, 33
 galanin system and, 74–75
 haplotype analysis and, 38
 Hardy-Weinberg equilibrium (HWE) and, 32–33, 36–38
 linkage analysis and, 34–37 (*see also* Linkage analysis)
 LOD scores and, 34–36, 46, 183–184
 McNemar test and, 29
 marker statistics and, 27–29, 32–43
 neuregulin 1 and, 76–77
 nicotinic receptors and, 77–78, 129
 NMDA and, 56, 76, 204, 249–250
 opioid system and, 72
 oxytocin and, 77
 Pearson's test and, 29–30, 33, 37
 pharmacogenetics and, 245–255
 power calculation and, 46–47
 proline dehydrogenase and, 76
 regressive model and, 31–32
 sample size and, 46–47
 schizophrenia and, 76, 195–208, 245–255
 statistical methods in, 27–47
 vasopressin and, 77
Neuropsychological genetics
 animal models and, 51–81
 complex phenotypes and, 16–19
 defined, 3
 emotion and, 3
 picking genes for study, 19–24
 transgenic mice and, 51–54
Newman, SK, 229
Nicastrin, 110
Nicodemus, Kristin K., 27–50
Nicotinic receptors, 77–78, 129
Niendam, TA, 196
Nieuwenstein, MR, 196
Nigeria, 21
Niwa, H, 57
N-methly-D-aspartate (NMDA), 56, 76, 204, 249–250
Noblett, KL, 147
Nolan, KA, 71, 199

Nonparametric linkage, 27
Norepinepherine system, 124
Norton, N, 250
Notch receptor, 199
Novel arm, 60
Nucleus accumbens, 68
Nucleus basalis magnocellularis lesions, 65
Nucleus basalis of Meynert, 224

Obesity, 12
Object recognition, 63–64
O'Brien, C, 100
Occult functions, 23
Octo Twin project, 99
Odor span task, 63
Ogden, CA, 136
Olanzapine, 247, 250
Old Testament, 5
Olfactory discrimination, 63, 69
Olfactory memory, 74
Olson, RK, 179, 182
OMIM (Online Mendelian Inheritance in Man), 22
Onchocerciasis, 19
Operant conditioning chamber, 64
Opioid system, 72
Oppenheim, JS, 126
Oral comprehension, 178–181
Oral pontine nucleus, 130–131
Orienting, 125, 129
Origin of Species, The (Darwin), 5
Orthographic coding (OC), 179
Out-of-bag test, 46
Owen, MJ, 206–207
Oxytocin (OT), 77

Pain
 avoidance and, 60
 shocks and, 60–61, 66, 68, 79
Paired helical filaments (PHFs), 223–224
Pair exchange, 7–8
Papaleo, Francesco, 51–94
Paracchini, S, 182
Paradee, W, 74
Parametric linkage, 27
Parasuraman, R, 168
Pardo, PJ, 126, 135
Parietal lobe, 125
Park, S, 198
Parkinson's disease, 70, 128, 224, 232
Parsey, RV, 150
Passingham, RE, 66
Passive avoidance, 60
Passive rGE, 106
Pastor, P, 232
Paterlini, M, 76
Paunio, T, 203
Pavlovian conditioning, 78
Payton, A, 169
PBAT software, 46
Pea hybrids, 5–7
Pearson, Karl, 5
Pearson test, 29–30, 33, 37
Pedersen, NL, 99, 167
Pedigree structure, 34–35
Pedunculopontine tegmental nucleus lesions, 65
Peier, AM, 74
Pennington, Bruce F., 101–102, 177–193
Perirhinal cortex, 59
Perphenazine, 247
Personality
 affective disorders and, 148
 broad brandwidth measures of, 148
 complex phenotypes and, 16–19
 corticolimbic function and, 147–148
 dopamine system and, 146–148
 emotional regulation and, 145–153
 environmental effects and, 3–4
 extraversion and, 146–147
 measures for, 17
 NEOAC measure and, 17
 serotonin and, 145–153
 threshold disorders and, 17, 19
 trait inheritance and, xi (*see also* Traits)
Petersen, RC, 224
Petersen, SE, 124

Petrill, SA, 99
Pezawas, L, 134–135, 151–152
Pharmacogenetics, 51
 advantages of, 245–246
 affective symptoms and, 245
 COMT and, 248–249
 confounds and, 253–255
 dopamine system and, 248–249
 ease of DNA sampling and, 245–246
 glutamate and, 249–253
 large-scale clinical trials and, 247, 254
 phenotypic candidates for, 246–248
 psychiatry and, 245–246
 second-generation antipsychotics (SGAs) and, 247, 250
 side effects and, 245–255
 technological advancements in, 245
 waiting game of, 245
Pharoah, PD, 40
Phase, 38
Phenocopies, 206
Phenotypes, xii
 Alzheimer's disease and, 221–235
 attentional deficits and, 200
 binary characteristics and, 27
 candidate gene association studies and, 37–39
 categorical analysis and, 27
 comorbidity and, 183–184
 complex, 16–19, 27
 component determination and, 30–32
 continuous characteristics and, 27
 dyslexia and, 177–181
 environmental factors and, 3–4, 43–46 (*see also* Environmental factors)
 epigenetic function control and, 12
 epistasis and, 43–46
 familial correlation and, 30–31
 family-based association test (FBAT) and, 39 (*see also* Family studies)
 Fisher's exact test and, 29
 genome-wide association (GWA) and, 27, 29, 39–43
 haplotype analysis and, 38
 Hardy-Weinberg equilibrium (HWE) and, 32–33, 36–38
 heritability and, 3–4 (*see also* Heritability)
 high-throughput genotyping platforms and, 39
 intelligence and, 97–114
 interclass correlation coefficient (ICC) and, 30–31
 intermediate, 195–197, 202–203
 linkage analysis and, 27–29, 34–37 (*see also* Linkage analysis)
 LOD scores and, 34–36, 46, 183–184
 McNemar test and, 29
 marker statistics and, 27–29, 32–43
 Pearson test and, 29–30, 33, 37
 pharmacogenetics and, 246–248
 regressive model and, 31–32
 schizophrenia and, 195–208, 245–255
 statistical genetics and, 27–47
 threshold disorders and, 17, 19
 transmission disequilibrium test (TDT) and, 29, 38–39
 variance in, 3–4
Phillips, AG, 62
Philosophers, 3
Phonological awareness (PA), 179
Phonological coding (PC), 179
Picciotto, MR, 55
Placebos, 250
Pleiotropy, 205
PLINK, 39
Plomin, R, 4, 98, 106–108, 112, 146, 208
Plougham, LM, 46
Pluripotent stage, 54
Poets, 3
Polderman, TJC, 98
Pollard, KS, 109
Polymerase chain reaction, 54
Polymorphisms, 9–15, 19
 Alzheimer's disease and, 233
 animal models and, 71
 attention and, 128–133
 cognitive aging and, 159, 167–170
 dyslexia and, 182

emotion and, 145–153
intelligence and, 107–111
schizophrenia and, 199–207, 249
SNPs and, 11 (*see also* SNPs (single nucleotide polymorphisms))
statistical genetics and, 22–24, 29
Pontecorvo, MJ, 80
Populations
candidate gene approaches and, 20
complex phenotypes and, 16–19
defined, 5
family studies and, 29–31 (*see also* Family studies; Twin studies)
International HAPMAP Project and, 21
linkage analysis and, 19–21 (*see also* Linkage analysis)
marker statistics and, 27–29, 32–43
quantitative traits and, 16–17
stratification and, 41, 43
subpopulation data and, 41–43
substructure and, 41
threshold disorders and, 17, 19
Porteous, DJ, 205
Positive FDR (pFDR), 40
Positron emission tomography (PET), 150, 153
Posner, Michael I., 123–144
Posterior cortical atrophy, 223
Posthuma, Danielle, 97–121
Poulos, AM, 59
Power calculation, 46–47
Powers, WF, 100
Prader-Willi syndrome, 12
Prasher, VP, 227, 232
Prefrontal cortex (PFC)
animal models and, 59, 61–62, 66
attention and, 128–129
decision making and, 68
dopamine system and, 71
schizophrenia and, 248–249, 254
shifting tasks and, 67
Prelimbic cortex, 62
Presenilins, 228–231
Price, AL, 42
Price, CJ, 181
Pritchard, JK, 43
Privacy issues, 125
Proline dehydrogenase (PRODH), 76–78
Promoter-inhibitor sites, 12–14
Proteins. *See also* Specific protein
Alzheimer's disease and, 221–235
amyloid precursor, 52
corticotropin-releasing factor (CRF) system and, 69–70
DNA coding and, 8–10
endocannabinoid system and, 72–73
functional variations and, 12–16
gene coding and, 9
posttranslational modification and, 15
transgenic mice and, 51–54
Psychosis susceptibility gene, 13
Punnet square, 6
Purcell, S, 39
p values, 40

Qin, W, 161
Quantitative trait loci (QTLs), 107
QUANTO software, 46
Quetiapine, 247
Quraishi, S, 195
q values, 40

Race, 20
Alzheimer's disease and, 230–231
intelligence and, 105, 109
migratory patterns and, 127
Radial maze, 62–63, 71, 75–76, 79
Ragozzino, ME, 67
Raitano, NA, 183
Ramakers, GJ, 109
Rampon, C, 76
Random-effect logistic models, 31
Random foraging task, 62–63
Random forest, 45
Raphe nuclei, 130–131
Rapid serial naming (RSN), 179, 184
Rats, 51, 68, 160

Raven's Matrices, 103–104
Raz, N, 102, 160, 200
Reaction time
 animal models and, 65–66, 68
 attention and, 128
 delayed response task and, 128
 inspection time and, 104
 intelligence and, 103–105
Reading comprehension, 177–181
Recessive traits, 6, 43
Recognition memory,
 attention and, 65–66
 change in habits and, 66
 decision making and, 68
 delayed comparison procedures and, 65
 extinction and, 66
 flexibility and, 67
 instrumental learning and, 64–65
 object, 63–64
 reaction time and, 68
 reversal learning and, 66
 shifting tasks and, 67
 social, 64
Recombination, 34
Record, RG, 101
Recursive partitioning, 46
Redon, R, 107
Reduced model, 43
Regression analysis, 31–32, 38, 40, 170
Reibaud, M, 72
Reich, DE, 127
Reif, A, 149
Reiman, EM, 232
Relative pair linkage method, 36
Religion, 4, 20
Renner, JA, 223
Ren-Patterson, RF, 152
Restifo, LL, 109
Retinoblastoma, 19
Rett syndrome (RS), 222–223
Reuter, M, 111, 133
Reversal learning, 66, 73
Reverse tTA (rtTA), 54
Reynolds, CA, 99
rGE correlations, 105–107
RGS4, 199
Rijsdijk, FV, 99, 103
Ringman, John M., 222–244
Risch, N, 33
Risk Evaluation and Education for
 Alzheimer's Disease study, 234
Risperidone, 247, 250
RNA (ribonucleic acid)
 attention and, 136
 corticotropin-releasing factor (CRF) system
  and, 69–70
 functional variation effects and, 12–16
 messenger, 9, 12–16, 22, 69–70, 136
 small interfering, 9
 splicing and, 10
RNA interference technology, 182
Robbins, TW, 65
Robertson, IH, 196
Rogaeva, E, 228, 234
Romeo, RD, 134
Ronalds, GA, 101
Rondi–Reig, L, 76
Rosa, A, 199, 248
Rosen, C, 124
Ross, MH, 227
Ross, RS, 61
Rosselli, MC, 229
Rossor, MN, 226
Rovelet-Lecrux, A, 225
Rowe, DC, 105, 185
Rowe, J, 228
Rubenstein, M, 137
Rueda, MR, 126, 133
Russia, 231
Rutter, M, 185
Ryan, CN, 68
Rybakowski, JK, 199
Rypma, B, 160

Sabeti, PC, 109
Sabol, SZ, 128

Sakai, N, 54
Salthouse, TA, 159
Sample size
 combination of samples and, 29
 Fisher's exact test and, 29
 importance of calculating, 46
 LOD scores and, 46
 statistical genetics and, 29, 46–47
Sanders, MJ, 72
Saoud, M, 201
Sarcosine, 250
Saura, CA, 229
Savatti, C, 40
Savitz, J, 111, 168
Savolainen, P, 4
Sawaguchi, T, 128
Scarborough, HS, 179, 181
Scerif, G, 133
Scerri, TS, 182
Schacter, DL, 171
Schaid, DJ, 38
Schaie, KW, 160
Schellenberg, GD, 228
Scheuner, D, 224, 226, 229
Schinka, JA, 147, 149
Schizoaffective disorder, 250–251
Schizophrenia, xi, 9, 19
 age-dependent performance deterioration and, 78
 attention and, 123, 127, 135, 195–196, 200–202
 BDNF and, 203, 206
 body mass index and, 207
 California Verbal Learning Test and, 202
 candidate gene approach and, 195–208
 childhood-onset, 109
 cognitive genes and, 200
 COMT and, 199, 201, 203, 206–207, 248–249, 253–254
 confounds and, 205–206
 Continuous Performance Tasks (CPT) and, 200–205
 CVLT and, 204
 DAOA and, 195–196, 199, 201, 204–205, 207–208, 252
 DARPP-32 and, 199–200
 declarative memory and, 202–203
 description of, 195
 DISC1 and, 8, 76, 79, 169, 195–196, 199, 204–206, 208, 253
 dopamine system and, 70, 199, 248–249, 254–255
 dysbindin and, 195, 199, 201, 206, 208, 250–252
 episodic memory and, 195, 202
 false positives and, 205
 family studies and, 192, 196, 198, 200–205, 246, 248–249
 flexible switching and, 201–202
 G72 and, 195
 genetic heterogeneity and, 205
 genome-wide association (GWA) and, 253–254
 GRM3 and, 201, 204, 206
 hallucinations and, 224
 heritability and, 192, 198, 201–205
 heterogeneous symptoms of, 195–196
 independent living and, 246
 information processing and, 196–197
 intelligence and, 112, 196–197, 200, 251–252, 254
 linkage analysis and, 198–200, 203
 literature findings on, 197–205
 Local Global Task and, 201–202
 marker identification and, 245
 memory and, 197–205, 248–249
 molecular genetics and, 201–205
 multiple testing and, 205
 N-back task and, 201, 206, 248, 254
 neuregulin 1 and, 76–77, 200, 253
 neurofibrillary tangles (NFTs) and, 223–225
 neuroimaging and, 195
 nicotinic receptors and, 78
 NMDA and, 195, 204, 249–250
 Notch4 and, 199
 NRG1 and, 195–196, 206
 pharmacogenetics and, 245–255

Schizophrenia (cont.)
phenotype identification methods and, 196–197
pleiotropy and, 205
proline dehydrogenase and, 76
putative susceptibility genes for, 233–235
RGS4 and, 199, 206
second-generation antipsychotics (SGAs) and, 247, 250
senile plaques and, 223–224
statistical issues and, 205–206
study conclusions on, 206–208
susceptibility genes and, 195–196, 206–208
task diversity and, 205
twin studies and, 198, 202–203, 205, 248–249
Warrington facial recognition subtest and, 202
Wechsler tests and, 198–204
Wisconsin Card Sorting Task and, 199, 202, 205
Schmidt, FL, 98
Schneider, JS, 128
Schoepp, DD, 253
Schork, NJ, 34
Schumacher, J, 182, 196
Schupf, N, 228
Schweimer, J, 68
Scottish studies, 97–98, 110, 169, 170–171
Scoville, WB, 202
Screening methods, 23
Seaman, SR, 40
Seamans, JK, 62, 128
Seattle Longitudinal Study, 160
Sebat, J, 11
Second-generation antipsychotics (SGAs). *See* Pharmacogenetics
Secreted frizzled-related protein 2 (sFRP2), 135–136
Seidenberg, MS, 179
Seidman, LJ, 202
Selective breeding, 4–5
Sen, S, 149
Senile plaques, 223–224, 227
Sensorimotor gating, 126
Sensory cortex, 59
Serotonin, 129
animal models and, 152–153
anxiety and, 145–153
attention and, 130, 133–134
cognitive aging and, 169–170
corticolimbic function and, 147–153
emotional regulation and, 145–153
extraversion and, 147–148
individual differences and, 150
neuroimaging and, 145
personality and, 147–148
Sesack, SR, 130
Sex, 6–8
Shamir, R, 40
Sheep, 5
Shenkin, SD, 100
Sherrington, R, 228, 231
Shields, J, 196
Shimizu, E, 76
Shioe, K, 150
Shocks, 60–61, 66, 68, 79
Sib pairs
affected, 36, 46
Hasemen-Elston regression and, 37
linkage analysis and, 36–37
transmission disequilibrium test (TDT) and, 38–39
Sidekick (SDK1), 136
Silberg, J, 185
Silva, AJ, 69
Sin3A-associated protein (SAP18), 136
Singleton studies, 100–101
SIR2 gene, 160
siRNA (small interfering RNAs), 9
Skin cancer, 5
Skinner box, 64
Skin pigmentation, 5, 43
SLC64A gene, 169–170
Slice variants, 10
Small, B, 110
Small, GW, 232
Smith, DR, 70

Smith, JD, 184
Smith, Shelley D., 177–193
SNAP-25 gene, 111–112
Snijders, T, 31
Snitz, BE, 200, 202
Snowdon, DA, 225
SNPs (single nucleotide polymorphisms), 11
 anxiety and, 151–152
 association studies and, 29
 attention and, 131
 cognitive aging and, 169, 171
 CpG islands and, 23
 functional variations and, 12–16
 gene picking methods and, 21–23
 genome-wide association (GWA) and, 27, 29, 39–43
 high-throughput genotyping platforms and, 39
 International HAPMAP Project and, 21
 likelihood ratio test (LRT) and, 43
 linkage disequilibrium (LD) and, 33–34
 marker statistics and, 27–29, 32–43
 multiple testing and, 39–41
 schizophrenia and, 204–205, 207
 tag, 23
 training set and, 45–46
 trend tests and, 38
 whole genome approach to intelligence and, 107–109
Sobin, C, 132
Social discrimination paradigm, 64
Social recognition, 64, 77
Social transmission of food preference (STFP) task, 60–61, 74
Solar (sequential oligogenic linkage analysis routines) software, 37
Soreq, H, 70
Southern blotting, 54
Span of Apprehension task, 126
Span task, 126, 169
Spearman, Charles, 5, 16, 97
Specific Language Impairment (SLI)-Consortium, 183
Speech sound disorder (SSD), 183–186
Speed-of-processing theory of intelligence, 103–105
Sperm, 6–8
Spielman, RS, 29, 38
Spinath, FM, 98, 103
Spine density, 160
Splicing, 10
Spontaneous Selective Attention Task, 126
Squire, LR, 59, 202
Staal, WG, 202
Standard deviation (SD), 17, 101, 110, 247, 251–252
Standard error, 44
Stanton, ME, 61
Statistical genetics
 allele frequency and, 32
 candidate gene association studies and, 37–39
 chi–square test and, 33, 37–38
 confidence interval (CI) and, 44–45
 confounding and, 41
 data mining algorithms and, 45
 epistasis and, 43–46
 familial correlation and, 27–31
 family-based association test (FBAT) and, 39
 fine mapping and, 27
 Fisher's exact test and, 29, 33
 gene-environment interaction and, 43–46
 genetic component determination and, 8–10, 30–32
 genome-wide association (GWA) and, 27, 29, 39–43
 haplotype analysis and, 38
 Hardy-Weinberg equilibrium (HWE) and, 32–33, 36–38
 high-throughput genotyping platforms and, 39
 interclass correlation coefficient (ICC) and, 30–31
 likelihood ratio test (LRT) and, 43, 45
 linkage analysis and, 27–29, 34–37
 linkage disequilibrium (LD) and, 33–34
 LOD score and, 34–36, 46
 marker, 32–34 (*see also* Marker statistics)
 migrant studies and, 27–28

Statistical genetics (cont.)
multiplex families and, 28
neuroimaging and, 23, 102–103, 123–124
nonparametric linkage and, 27
parametric linkage and, 27
Pearson test and, 29–30, 33, 37
power calculations and, 46–47
random forest and, 45
recursive partitioning and, 46
regressive model and, 31–32
sample size and, 46–47
schizophrenia and, 205–206
standard deviation (SD) and, 17, 101, 110, 247, 251–252
standard error and, 44
training set and, 45–46
transmission disequilibrium test (TDT) and, 29, 38–39
twin studies and, 27–28
variance component and, 27
Staubli, U, 61
Stefanis, NC, 200, 207
Steiner, RA, 52, 74
Stern, CE, 66, 227
Sternberg, RJ, 97
Stolnick, SD, 171
Storey, JD, 40
Storfer, M, 102
Stough, C, 104
Stranger, BE, 40
Striatum, 70–71
Strobel, A, 147
Stroop task, 125
Structural equation modeling, 102
STRUCTURE, 42–43
Stutzmann, GE, 131, 134
Su, AI, 136
Subiculum, 59
Sugino, K, 135
Sun, L, 40
Superior temporal lobe, 125
Supralemniscal group, 130–131
Sur, M, 137
Survival of the fittest, 5
Swearer, JM, 226
Swedish Adoption Twin Study of Aging, 99
Swedish Twin Registry, 99

Tachykinin precursor 1 (TAC1), 135–136
Taghzouti, K, 66
Tag markers, 21, 23
Taipale, M, 182
Takeda, A, 136
Tan, HY, 206, 253
Tan, W, 14
Tan, YL, 203
Tang, MX, 231
Tanzi, RE, 233
TaqIA polymorphism, 131–132
Tatum, EL, 9
Techykinin, 135
Tesseur, I, 233
Tetracycline transactivator (tTA), 53–54
Tgf-alpha, 134
Thomas, DC, 40–41
Thomas, KR, 54
Thompson, PM, 101, 110, 126
Thompson, R, 61
Threshold disorders, 17, 19
Tibshirani, R, 40
Tillerson, JL, 71
Tischfield, JA, 137
Tissue-specific transgenic mouse technology, 52–53
T-maze, 61–62, 67–68, 70–71, 76
Tokuda, T, 227
Tomie, JA, 78–79
Toulopoulou, T, 202
Tournoy, J, 229
Tower test, 168
Traditional knockout technology, 54–55
Trails Making Test, 199, 230
Training set, 45–46
Traits
Alzheimer's disease and, 221–235
brain reaction diversity and, 10–11

brain volume and, 101–103
brief history of genetics and, 4–24
chromosomes and, 6–8 (*see also* Chromosomes)
complex phenotypes and, 16–19, 27
component determination and, 30–32
crossover events and, 8
cross-trait cross-twin correlation and, 102
dominant, 6, 43
environmental factors and, 11, 43–46
epistasis and, 43–46
familial correlation and, 27–31
family-based association test (FBAT) and, 39 (*see also* Family studies)
genetic component determination and, 30–32
genetic distance and, 7
intelligence and, 97–114
linkage analysis and, 34–37
Mendel and, 6, 19
NEOAC measure and, 17
Punnet square and, 6
quantitative, 16–17, 107
random distribution and, 7, 31
recessive, 6, 43
regressive model and, 31–32
schizophrenia and, 195–208, 245–255
selective breeding and, 4–5
statistical genetics and, 27–47
Tramo, MJ, 126
Trandafir, A, 246
Transcription phase, 13–14, 23
Transgenic mice, 51–54, 74, 80–81, 234–235
Translocations, 8
Transmission disequilibrium test (TDT), 29, 38–39
Trend test, 38
Trisomy 18, 8
Trisomy 21, 8
Trommer, BL, 232
Tryptophan hydroxylase (TPH), 133, 151–152
Tsai, G, 250
Tsai, SJ, 71, 111, 199, 248
Tsien, JZ, 76
Tubby homologue (TUB), 136
Tulving, E, 202
Tunick, RA, 183
Turkheimer, E, 105, 185
Tuulio-Henriksson, A, 198
Twin-singleton studies, 100–101
Twin studies, 4, 27
attention and, 126
cognitive aging and, 161, 167, 170
cross-trait cross-twin correlation and, 102
dizygotic (DZ) twins, 28, 30, 99, 102–106, 161, 167, 169, 198, 203
environmental factors and, 98–99
heterozygotic twins, 32, 38, 69, 71, 75, 77, 111
homozygotic twins, 32, 51, 75, 77, 79, 111, 136, 169–171, 204, 248–249
intelligence and, 98–106, 111
monozygotic (MZ) twins, 28, 30, 99, 102–106, 126, 161, 167, 198, 202–203
schizophrenia and, 198, 202–203, 205, 248–249
separate rearing and, 99
socioeconomic status and, 98
Tyrosine kinase receptor (TrkB), 75–77

Ubiquilin, 233
UCSC genome browser, 22–23
United Kingdom, 226
U.S. National Institute on Aging Late-Onset Alzheimer
Disease study, 233
Utah, 131
Utermann, G, 231

Valine allele, 129
van Baal, GCM, 98
van Gaalen, MM, 68
Van Valen, L, 102
van Veen, V, 135
Variable number tandem repeats (VNTRs)
bioinformatics and, 11
marker statistics and, 27–29, 32–43

Variance components
 family studies and, 30–31
 linkage analysis and, 34–37
 marker statistics and, 27–29, 32–43
 regressive model and, 31–32
Variance-covariance matrix, 44–45
Variance-variance matrix, 44–45
Varvel, SA, 63, 73
Vasopressin (AVP), 77
Ventral striatum, 66
Verbal learning task, 169
Vernon, PA, 103
Vision
 Alzheimer's disease and, 223
 attention and, 123–137
 inspection time and, 104
 macular degeneration and, 19
 mazes and, 58–63, 67–79
 memory and, 203
 shifting tasks and, 67
 smooth pursuit eye tracking and, 126
 Span of Apprehension task and, 126
Vitamin D, 5
Vogt, BA, 135
Voight, BF, 109
von Melchner, H, 57
Vyssotski, AL, 76

Waggoner, SG, 225
Wainwright, MA, 108
Wakutani, Y, 226
Walsh, B, 32
Walton, ME, 68
Wang, H, 69
Warren, DM, 37
Warrington facial recognition subtest, 202
Wassink, TH, 199
Watanabe, K, 128
Watkins, LR, 151
Webbink, D, 101
Wechsler Adult Intelligence Scale (WAIS), 27, 102, 104, 199–200
Wechsler Memory Scale (WMS), 198–199, 201, 203–204
Wechsler Working Memory tasks, 198
Weickert, CS, 251
Weickert, TW, 248–249
Weight, 16
Weighted FDR, 40
Weinberger, Daniel R.
 animal models and, 51–94
 attention and, 123, 133
 emotion and, 150
 molecular genetics and, 3–26
 schizophrenia and, 196–197, 248
Werner's syndrome, 161, 169
Westminster Dog Show, 5
Wetter, SR, 232
Whishaw, IQ, 78–79
White, NM, 63
Whittemore, AS, 40
Whyte, MC, 203
Wickett, JC, 102
Wiedenmayer, CP, 69
Wijsman, EM, 232
Willcutt, E, 183
Willerman, L, 102
Williams, GV, 249
Williams, NM, 252
Williams-Beuren syndrome, 11–12
Williams syndrome, 109, 123, 133
Win-shift radial maze, 71
Winstanley, CA, 68
Winterer, G, 70
Wisconsin Card Sorting Test, 67, 128, 199, 202, 205, 230
Wisniewski, K, 224
Witte, EA, 124
Woodward, 248–249
Working memory (WM)
 animal models and, 61–65
 schizophrenia and, 195, 197–200, 205, 248–249
Wrenn, CC, 74
WRN gene, 161
Wyatt, RJ, 245

Xu, K, 123

Y-maze, 60
Young, JW, 63, 65, 78
Young, LJ, 77

Zaykin, DV, 40
Zhang, Fengyu, 27–50
Zhang, H, 112
Zhang, J, 109
Zhang, Y, 61
Zheng, G, 46
Zhivotovsky, LA, 40
Zimmer, A, 72
Zinc transporter (SLC39A5), 136
Ziprasidone, 247
Zola, SM, 59, 202
Zygotes, 8. *See also* Twin studies